Summary
Pfizer Inc. (PFE) filed an 8-K on April 27, 2012, reporting the results of its Annual Meeting of Shareholders held on April 26, 2012. The primary focus of this filing is the shareholder voting outcomes on various proposals. All director nominees were elected for one-year terms with substantial support. Shareholders also ratified the appointment of KPMG LLP as the independent registered public accounting firm for 2012 and approved, on an advisory basis, the compensation of the company's Named Executive Officers. Several shareholder proposals, including those related to political contributions, action by written consent, special shareholder meetings, and an advisory vote on director pay, did not receive majority approval from shareholders.
Key Highlights
- 1All director nominees for Pfizer's Board of Directors were elected for one-year terms with significant majority votes.
- 2Shareholders overwhelmingly approved the ratification of KPMG LLP as Pfizer's independent registered public accounting firm for 2012.
- 3An advisory vote on the compensation of the Company's Named Executive Officers was approved by shareholders.
- 4A shareholder proposal regarding the publication of political contributions was not approved, receiving substantial opposition.
- 5A shareholder proposal concerning the ability of shareholders to act by written consent also failed to gain majority approval.
- 6A shareholder proposal advocating for special shareholder meetings did not pass, with a majority voting against it.
- 7An advisory vote on director pay, as presented by shareholders, was not approved, indicating shareholder dissent on this specific issue.